Breakout Ventures closed its third vehicle, Fund III, a $114 million venture fund focused on AI-powered science startups, led by founders Lindy Fishburne and Julia Moore. The fund targets companies where computation and the lab bench converge, featuring investments designed to speed translation from biology research into medicines and materials.
Fund III will back companies from pre-seed through Series A and continued Breakout’s pattern of writing early institutional checks. The firm added partners with domain expertise, including diagnostics founder Dana Watt and organic chemist Nima Ronaghi, and highlighted portfolio names such as Noetik, Phantom Neuro and ZymoChem as examples.
For entrepreneurs and researchers, the fund signals growing investor conviction that AI-native approaches can compress discovery timelines and create scientific moats. By concentrating capital on scientist-founders who build engineering-minded labs, Breakout aims to accelerate commercially viable advances across drug discovery, diagnostics, neurotechnology and bio-based materials.
AI-Driven Science Funds
Breakout Ventures Closes Fund III at $114 Million
Trend Themes
-
AI-native Labs — Laboratories designed around machine learning and automation enable rapid hypothesis testing and iterative experiments that shorten R&D cycles and create defensible technical advantages.
-
Computational-translation Convergence — The tight integration of in silico modeling with bench biology accelerates the path from discovery to prototypes, reshaping how novel therapeutics and materials are validated and scaled.
-
Early-stage Deeptech Funding — Concentrated capital for pre-seed to Series A science startups increases runway for high-risk, high-reward platforms, shifting investor expectations toward platform-level value creation rather than single-product bets.
Industry Implications
-
Drug Discovery — Algorithm-driven target identification and predictive chemistry are enabling faster lead generation and reduced experimental attrition, transforming timelines for bringing drug candidates to clinical readiness.
-
Diagnostics — AI-enhanced assay design and pattern-recognition analytics are permitting earlier, more precise detection modalities that redefine clinical decision-making and monitoring.
-
Bio-based Materials — Computational protein and polymer design coupled with automated prototyping is opening pathways to sustainably sourced materials with tailored properties previously unreachable by traditional chemistry.